Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia.
In: Journal of Clinical Endocrinology & Metabolism, Jg. 106 (2021-05-01), Heft 5, S. e2063- (15S.)
Online
academicJournal
Zugriff:
Context: Standard glucocorticoid therapy in congenital adrenal hyperplasia (CAH) regularly fails to control androgen excess, causing glucocorticoid overexposure and poor health outcomes. Objective: We investigated whether modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol secretion, could improve disease control. Methods: A 6-month, randomized, phase 3 study was conducted of MR-HC vs standard glucocorticoid, followed by a single-arm MR-HC extension study. Primary outcomes were change in 24-hour SD score (SDS) of androgen precursor 17-hydroxyprogesterone (17OHP) for phase 3, and efficacy, safety and tolerability of MR-HC for the extension study. Results: The phase 3 study recruited 122 adult CAH patients. Although the study failed its primary outcome at 6 months, there was evidence of better biochemical control on MR-HC, with lower 17OHP SDS at 4 (P = .007) and 12 (P = .019) weeks, and between 07:00h to 15:00h (P = .044) at 6 months. The percentage of patients with controlled 09:00h serum 17OHP (< 1200 ng/dL) was 52% at baseline, at 6 months 91% for MR-HC and 71% for standard therapy (P = .002), and 80% for MR-HC at 18 months' extension. The median daily hydrocortisone dose was 25 mg at baseline, at 6 months 31 mg for standard therapy, and 30 mg for MR-HC, and after 18 months 20 mg MR-HC. Three adrenal crises occurred in phase 3, none on MR-HC and 4 in the extension study. MR-HC resulted in patient-reported benefit including menses restoration in 8 patients (1 on standard therapy), and 3 patient and 4 partner pregnancies (none on standard therapy). Conclusion: MR-HC improved biochemical disease control in adults with reduction in steroid dose over time and patient-reported benefit. [ABSTRACT FROM AUTHOR]
Copyright of Journal of Clinical Endocrinology & Metabolism is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia.
|
---|---|
Autor/in / Beteiligte Person: | Merke, Deborah P. ; Mallappa, Ashwini ; Arlt, Wiebke ; de la Perriere, Aude Brac ; Hirschberg, Angelica Lindén ; Juul, Anders ; Newell-Price, John ; Perry, Colin G. ; Prete, Alessandro ; Aled Rees, D. ; Reisch, Nicole ; Stikkelbroeck, Nike ; Touraine, Philippe ; Maltby, Kerry ; Peter Treasure, F. ; Porter, John ; Ross, Richard J. ; Brac de la Perriere, Aude ; Lindén Hirschberg, Angelica ; Rees, D Aled |
Link: | |
Zeitschrift: | Journal of Clinical Endocrinology & Metabolism, Jg. 106 (2021-05-01), Heft 5, S. e2063- (15S.) |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 0021-972X (print) |
DOI: | 10.1210/clinem/dgab051 |
Schlagwort: |
|
Sonstiges: |
|